Description
Seeking men and women who have been diagnosed with metastatic non-small cell lung cancer with STK11, KEAP1, or KRAS genetic mutations and have not yet started treatment for a study comparing an investigational drug combination to the standard drug combination.
Overview
Participants in this study will receive either the investigational or the standard drug combination and they, their medical providers and study staff will know what drug combination they will receive. There will be study visits every 3 to 4 weeks. Participation will stop if they are no longer benefitting from it.
What we're hoping for
We are studying if durvalumab plus tremelimumab with chemotherapy is safe and how well it works compared to pembrolizumab with chemotherapy in people with newly diagnosed metastatic non-small cell lung cancer with certain genetic mutations.
Additional Information
ClinicalTrials.gov Identifier: NCT06008093